Interlaboratory method validation of capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) methodology for analysis of mAbs. Issue 19 (6th August 2021)

• Record Type: Journal Article
• Authors: Li, Meng; Yu, Chuanfei; Wang, Wenbo; Wu, Gang; Wang, Lan
• Is Part Of: Electrophoresis. Volume 42:Issue 19(2021)
• Page Start: 1900
• Page End: 1913
• Publication Date: 2021-08-06
• Subjects: Capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) -- ICH guideline -- Monoclonal antibody (mAb); Electrophoresis -- Periodicals; Electrophoresis -- Periodicals; 541.372
• DOI: 10.1002/elps.202000396
• Languages: English
• ISSNs: 0173-0835

Abstract

Abstract: Capillary electrophoresis sodium dodecyl sulfate (CE‐SDS) is an analytical method to assess the purity of proteins, commonly applied to monoclonal antibodies (mAbs) in the biopharmaceutical industry. To address the need to standardize the CE‐SDS method in the pharmaceutical industry and to enhance the confidence in method transfer between laboratories operating different commercial capillary electrophoresis (CE) instrument platforms, an interlaboratory CE‐SDS method validation was organized involving 13 laboratories in 13 companies on four different types of commercial capillary electrophoresis instruments. In the validation, a commercial mAb therapeutic was used as the sample. The validation process followed the analytical guidelines set by the ICH guidelines (International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). The method's precision, accuracy, linearity and range, and limit of quantitation (LOQ) were validated in the study. Variations of all the parameters validated in the study passed the pre‐set criteria defined at the beginning of the study. The definition was based on previously published works and the intended application purpose of the CE‐SDS method for mAbs. The study proved that the CE‐SDS method fits its intended application purpose as a size impurity assay and size heterogeneity characterization assay for mAb therapeutic products. This study is the first time a CE‐SDS method is validated by multiple laboratories using different commercial CE instrument platforms and on a commercial mAb therapeutic. Its results will enhance the confidence of the biopharmaceutical industry to develop CE‐SDS methods and transfer CE‐SDS methods between different laboratories.